| 1 |
35426132 | The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin. | 2022 Jul |
1 |
| 2 |
35620290 | Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials. | 2022 |
1 |
| 3 |
34109627 | PharmVar GeneFocus: CYP2C9. | 2021 Sep |
1 |
| 4 |
30088221 | Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects. | 2019 Mar |
9 |
| 5 |
31199498 | Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations. | 2019 Nov |
2 |
| 6 |
31392364 | Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. | 2019 Nov |
2 |
| 7 |
29273968 | In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. | 2018 Apr |
12 |
| 8 |
30105453 | Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. | 2018 Dec |
2 |